and a semi asset-light business model, despite market challenges. LSTR's prudent pricing strategies, diversified service offerings, and stable cost management drive its stable topline performance ...

The agreements include $200 million in data licensing and model development fees to Tempus. The agreement with AstraZeneca expands on the strategic partnership between the two companies announced ...